Name of Trial: REMoDL-B
Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib
Type of Trial
On-going. Studying addition of bortezomib to standard rituximab with cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) therapy in treatment of Diffuse Large B-cell Lymphoma (DLBCL).
Overall survival, Event-free survival, Disease-free survival, Time to progression, Response duration, Complete and overall response rates, Evaluation of toxicity, Quality of life and assessment of peripheral neuropathy.
Criticisms and Limitations
Study not completed yet.
Clinical Trial Websites
Relevant Clinical Literature